Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 9/20 | 0.45 |
| ▸ | PLK1 | P53350 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16757612 | 1.00 | TLR2 (0.45) | TLR2PLK1CA2MEN1KMT2A | |
| SCHEMBL31463228 | 0.91 | PLK1 (0.42) | TLR2PLK1CA2MEN1KMT2A | |
| SCHEMBL16791114 | 0.89 | PLK1 (0.42) | TLR2PLK1CA2MEN1KMT2A | |
| SCHEMBL29131983 | 0.89 | PLK1 (0.42) | TLR2PLK1CA2MEN1KMT2A | |
| SCHEMBL16757623 | 0.89 | MEN1 (0.43) | TLR2PLK1CA2MEN1KMT2A | |
| SCHEMBL23417972 | 0.89 | TLR2 (0.44) | TLR2PLK1CA2MEN1KMT2A | |
| SCHEMBL31756841 | 0.89 | PLK1 (0.42) | TLR2PLK1CA2MEN1KMT2A | |
| SCHEMBL16757624 | 0.89 | MEN1 (0.43) | TLR2PLK1CA2MEN1KMT2A | |
| SCHEMBL26232048 | 0.89 | PLK1 (0.42) | TLR2PLK1CA2MEN1KMT2A | |
| SCHEMBL26689222 | 0.83 | MEN1 (0.47) | TLR2CA2MEN1KMT2ADPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115504924-A | Hydrazino-pyrrolo compounds and methods for forming conjugates | 雷德伍德生物科技股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-105744935-B | Hydrazino-pyrrolo compounds and methods for forming conjugates | 雷德伍德生物科技股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-106456608-B | anti-HER 2 antibody-maytansinoid conjugates and methods of use thereof | 雷德伍德生物科技股份有限公司 | 2020-08-28 | — | — | CN | disclosed |
| US-10604483-B2 | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | REDWOOD BIOSCIENCE, INC. (US) | 2020-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604483-B2 | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | DNPEP, QPCT, PDS5A | TLR2 4743/4885PLK1 304/4885CA2 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.